Revance Therapeutics Inc (OQ:RVNC)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 1222 Demonbreun Street, Suite 2000
NASHVILLE TN 37203
Tel: 1-510-2796886
Website: https://www.revance.com
IR: See website
<
Key People
Mark J. Foley
Chief Executive Officer, Director
Tobin C. Schilke
Chief Financial Officer
David A. Hollander
Chief Medical Officer, Global Therapeutics Franchise Lead
Erica Jordan
Chief Commercial Officer
Dwight Moxie
Chief Legal Officer
 
Business Overview
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Financial Overview
For the three months ended 31 March 2024, Revance Therapeutics Inc revenues increased 13% to $51.9M. Net loss before extraordinary items increased 2% to $49.5M. Revenues reflect Collaboration revenue increase of 87% to $217K. Higher net loss reflects Selling and Adminstative balance increase of 22% to $60.2M (expense), Interest expense - Balancing value increase of 33% to $5.2M (expense).
Employees: 534 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $468.20M as of Mar 31, 2024
Annual revenue (TTM): $236.65M as of Mar 31, 2024
EBITDA (TTM): -$201.00M as of Mar 31, 2024
Net annual income (TTM): -$313.72M as of Mar 31, 2024
Free cash flow (TTM): -$220.74M as of Mar 31, 2024
Net Debt Last Fiscal Year: $152.77M as of Mar 31, 2024
Shares outstanding: 104,448,502 as of Apr 30, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.